Your session is about to expire
← Back to Search
Belantamab Mafodotin + Lenalidomide for Multiple Myeloma
Study Summary
This trial is testing a new treatment for multiple myeloma that may help patients achieve remission.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 trial • 6 Patients • NCT04177823Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot become pregnant due to my age or medical reasons.I agree to use contraception or practice abstinence.I have an active kidney condition.You have tested positive for hepatitis C unless you meet specific criteria.I have not had major surgery in the last 4 weeks.I am currently experiencing bleeding from an internal organ or mucosa.I am currently being treated for an infection.I have Hepatitis B but meet the specific criteria for treatment.I have no other cancers, or they've been stable for 2 years.I haven't taken any new or approved myeloma drugs recently.I do not have any serious or unstable health or mental conditions.I have been diagnosed with plasma cell leukemia.I have been treated with a monoclonal antibody recently.My organs are working well.I am able to care for myself but cannot do any heavy physical work.All my side effects from previous treatments are mild, except for hair loss.I recently had my first stem cell transplant for multiple myeloma.My cancer shows signs of responding to treatment or is undetectable.I will not donate sperm during and for 4 weeks after my last dose of lenalidomide.I have a current eye surface condition.My multiple myeloma does not produce detectable levels of M protein.My cancer has worsened before starting maintenance therapy.I have been diagnosed with smoldering multiple myeloma.I am HIV positive.I am at risk for heart disease.I am between 18 and 75 years old.My liver condition is stable.I agree not to donate blood while on lenalidomide and for 28 days after.
- Group 1: Belantamab mafodotin
- Group 2: Lenalidomide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What potential hazards are associated with Belantamab mafodotin?
"Taking into account the lack of evidence regarding efficacy, Belantamab mafodotin was assigned a safety score of 2."
What is the current participant count for this experiment?
"As of October 29th 2021, this trial is no longer enrolling patients. It was first posted on April 30th 2022 and has not been edited since then. Fortunately, 859 trials are available for those seeking treatment for multiple myeloma and a further 293 studies require participants taking Belantamab mafodotin."
What maladies is Belantamab mafodotin typically employed to treat?
"Belantamab mafodotin is widely used to combat chronic lymphocytic leukemia, but may also be deployed for those with amyloidosis or relapsed/refractory multiple myeloma who have received at least two prior systemic chemotherapy regimens."
Is enrollment still open for this clinical investigation?
"On clinicaltrials.gov, this medical experiment is not currently enrolling patients; the trial was first posted to the website on April 30th 2022 and lately updated October 29th 2021. Nonetheless, 1152 other studies are actively searching for participants presently."
Share this study with friends
Copy Link
Messenger